MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.23

+0.3%

3:05 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	5/5/2009 12:53:57 AM
	of 2240

FDA Advisory Committee to Review Arzerra(TM) (Ofatumumab) Summary: the FDA's Oncologic Drug Advisory Committee Will Hold a Meeting to Review the Arzerra BLA On May 29, 2009 COPENHAGEN, Denmark, May 4, 2009 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN.CO - News) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will hold a meeting on May 29, 2009 to review the Arzerra(TM) (ofatumumab) Biologics License Application (BLA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy. Genmab and GlaxoSmithKline submitted the BLA in January 2009 and announced that the FDA accepted it for review in April 2009. The FDA has granted ofatumumab priority review status. About ofatumumab Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available. The CD20 molecule is a key target in CLL therapy because it is expressed on most B-cells in CLL patients. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country. From its 2008 Annual report, MEDX still holds a bit over %5 of Genmab. Jason

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next